ELAC2 is a functional prostate cancer risk allele

Steven Blinka; Rashmi Mishra; Andrew C Hsieh

doi:10.1016/j.molmed.2023.06.002

ELAC2 is a functional prostate cancer risk allele

Trends Mol Med. 2023 Aug;29(8):586-588. doi: 10.1016/j.molmed.2023.06.002. Epub 2023 Jun 21.

Authors

Steven Blinka¹, Rashmi Mishra², Andrew C Hsieh³

Affiliations

¹ Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; School of Medicine, University of Washington, Seattle, WA 98195, USA.
² Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
³ Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; School of Medicine, University of Washington, Seattle, WA 98195, USA. Electronic address: ahsieh@fredhutch.org.

PMID: 37353407
PMCID: PMC10527048 (available on 2024-08-01)
DOI: 10.1016/j.molmed.2023.06.002

Abstract

Stentenbach and colleagues have unveiled a functional role of a human germline mutation found in the ribonuclease (RNase) Z enzyme, ELAC2, in prostate cancer. Here, we discuss the importance of these findings in enhancing our understanding of how risk variants enable prostate cancer progression and the post-transcriptional mechanisms underlying oncogenesis.

Keywords: ELAC2; prostate cancer; tRNA; translation control.

MeSH terms

Alleles
Genetic Predisposition to Disease
Humans
Male
Neoplasm Proteins / genetics
Prostatic Neoplasms* / genetics

Substances

ELAC2 protein, human
Neoplasm Proteins

Abstract

MeSH terms

Substances

Grants and funding